- Results of a Phase II / Proof-of-Concept Trial Assessing NEO6860 in Osteoarthritis Knee Pain and Dosing Considerations, 11th Annual Pain & Migraine Therapeutics Summit, San Diego, CA - Sept. 27-28, 2017
- NEO6860, a Modality Selective TRPV1 Antagonist: Pharmacodynamics Analysis following Intradermal Capsaicin Injection during a Phase 1 Study, 11th Annual Pain & Migraine Therapeutics Summit, San Diego, CA - Sept. 27-28, 2017
- NEO6860, a Novel Modality Selective TRPV1 Antagonist: Results from a Phase I, Double-Blind, Placebo-Controlled Study in Healthy Subjects. 35th Annual Scientific Meeting, American Pain Society. Austin, TX. May 11-14, 2016.
- Novel BET Bromodomain Inhibitors EP31670, EP11313 and EP11336 Have Potent Anti-Leukemic Activity in Acute Myeloid Leukemia (AML) and Augment the Effects of All-Trans-Retinoic Acid (ATRA) In Vitro. ASH 57th Annual Meeting. Orlando, FL. Dec 5-8, 2015.
